Abstract 115P
Background
Cholangiocarcinoma (CCA) comprises a heterogeneous group of cancers with bad prognosis. Krüppel-like factors (KLF) are a family of transcription factors involved in organogenesis, differentiation and cellular homeostasis. Here, we studied the role of KLF5 in CCA development and evaluated the therapeutic potential of its inhibition.
Methods
KLF5 expression was measured in human CCA tissues [Copenhagen (n=210), TCGA (n=36), Job (n=78), TIGER-LC (n=90) and San Sebastian cohorts (n=12)] and cell lines. KLF5 -/- CCA cells were created by CRISPR/Cas9. The functional effects of KLF5 genetic silencing with CRISPR technology, or chemical inhibition with ML264, were evaluated in vitro and in vivo.
Results
KLF5 expression was upregulated in human CCA tissues from 5 different patient cohorts compared to surrounding normal liver tissue. High KLF5 levels correlated with lymph node invasion and worse overall survival. In vitro, KLF5 protein and mRNA levels were overexpressed in human CCA cells compared to normal human cholangiocytes. Functionally, KLF5 -/- CCA cells displayed decreased cell proliferation, migration, invasion and colony formation while promoting cell cycle arrest at G1/S and apoptosis in vitro, when compared to control cells. In agreement, KLF5 -/- CCA cells did not develop any tumor after subcutaneous or orthotopic injection in a xenograft animal model of CCA. Likewise, chemical inhibition of KLF5 with ML264 hampered CCA cells proliferation and migration in vitro and blocked tumor growth in vivo. Lastly, both genetic and chemical inhibition of KLF5 sensitized CCA cells to chemotherapy-induced apoptosis in vitro, and the combination of gemcitabine + cisplatin and ML264 completely halted CCA tumor growth in mice. Accordingly, KLF5 -/- CCA display altered levels of several proteins related to chemoresistance when compared to control cells, that were shown to significantly correlate with KLF5 expression in human CCA tissues.
Conclusions
Increased KLF5 is a general event in CCA, contributing to cancer progression and chemoresistance. KLF5 inhibition with ML264 may represent a potential therapeutic strategy for CCA.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Biodonostia Health Research Institute.
Funding
Carlos III Health Insistute - FIS Project.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
669P - Patient-reported outcomes with selpercatinib in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial
Presenter: Hyunseok Kang
Session: Poster session 17
670P - Preliminary efficacy and safety of tinengotinib (TT-00420) monotherapy in Chinese patients (pts) with advanced solid tumors: Results from a phase Ib/II study
Presenter: Panpan Zhang
Session: Poster session 17
671P - Safety and efficacy of PM060184 plus gemcitabine in advanced solid tumors
Presenter: Sanjay Goel
Session: Poster session 17
672P - Phase I/II trial of RVU120 (SEL120), CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors
Presenter: Rafal Dziadziuszko
Session: Poster session 17
673P - A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours
Presenter: Patrick Schoeffski
Session: Poster session 17
674P - Response of thrombopoietin receptor agonists in MDM2 inhibitor induced thrombocytopenia
Presenter: Raymond DeMatteo
Session: Poster session 17
675P - A phase I study of safety, pharmacokinetics, and pharmacodynamics of SCR-6920, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced malignant tumors
Presenter: Jinming Yu
Session: Poster session 17
676P - Preclinical characterization of novel peptide binders for EphA2-targeted radiopharmaceutical therapy
Presenter: Renee Clift
Session: Poster session 17
677P - Preliminary findings from a phase I, open-label, dose-finding study of SNB-101 in patients with advanced solid tumors
Presenter: Yun Beom Sang
Session: Poster session 17
678P - ExoDS: A bioengineered exosome-based capsule for targeted delivery of chemotherapy drugs to cancer cells and cancer stem cells
Presenter: Abhishek Dutta
Session: Poster session 17